PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35468992-7	2022	Among the 64 compounds tested, 6-O-angeloylplenolin (6-OAP), a sesquiterpene lactone in Chinese medicinal herb Centipeda minima (CM), represented the most potent ACE2 repressor.	6-O-angeloylprenolin	31-51	angiotensin converting enzyme 2	Homo sapiens	162-166
35468992-7	2022	Among the 64 compounds tested, 6-O-angeloylplenolin (6-OAP), a sesquiterpene lactone in Chinese medicinal herb Centipeda minima (CM), represented the most potent ACE2 repressor.	6-O-angeloylprenolin	53-58	angiotensin converting enzyme 2	Homo sapiens	162-166
35468992-8	2022	6-OAP (2.5 microM) inhibited the interaction between Stat3 protein and ACE2 promoter, thus suppressed ACE2 transcription.	6-O-angeloylprenolin	0-5	angiotensin converting enzyme 2	Homo sapiens	71-75
35468992-8	2022	6-OAP (2.5 microM) inhibited the interaction between Stat3 protein and ACE2 promoter, thus suppressed ACE2 transcription.	6-O-angeloylprenolin	0-5	angiotensin converting enzyme 2	Homo sapiens	102-106
35468992-8	2022	6-OAP (2.5 microM) inhibited the interaction between Stat3 protein and ACE2 promoter, thus suppressed ACE2 transcription.	6-O-angeloylprenolin	0-5	signal transducer and activator of transcription 3	Homo sapiens	53-58
31139305-9	2019	In addition, four sesquiterpenoids were isolated from C. minima to identify the bioactive components responsible for the antioxidant activity of C. minima; 6-O-angeloylplenolin and arnicolide D were found to be the active compounds responsible for the activation of the Nrf2 signaling pathway and inhibition of ROS production.	6-O-angeloylprenolin	156-176	nuclear factor, erythroid derived 2, like 2	Mus musculus	270-274
29928343-2	2018	In the present study, 6-O-angeloylplenolin repressed the overexpression of ATP binding cassette subfamily B member 1 (MDR1) and increasing the intracellular concentration of anticancer drugs.	6-O-angeloylprenolin	22-42	ATP binding cassette subfamily B member 1	Homo sapiens	75-116
29928343-2	2018	In the present study, 6-O-angeloylplenolin repressed the overexpression of ATP binding cassette subfamily B member 1 (MDR1) and increasing the intracellular concentration of anticancer drugs.	6-O-angeloylprenolin	22-42	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
29928343-3	2018	A reduction in P-glycoprotein expression (encoded by MDR1) was observed in parallel with a decline in mRNA expression in vincristine-resistant HCT (HCT-8/VCR) cells treated with 6-O-angeloylplenolin.	6-O-angeloylprenolin	178-198	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
29928343-4	2018	In addition, 6-O-angeloylplenolin suppressed the activity of the MDR1 gene promoter.	6-O-angeloylprenolin	13-33	ATP binding cassette subfamily B member 1	Homo sapiens	65-69
29928343-5	2018	Treatment with 6-O-angeloylplenolin also decreased the amount of the specific protein complex that interacted with the MDR1 gene promoter in HCT-8/VCR cells, potentially leading to the suppression of MDR1 expression.	6-O-angeloylprenolin	15-35	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
29928343-5	2018	Treatment with 6-O-angeloylplenolin also decreased the amount of the specific protein complex that interacted with the MDR1 gene promoter in HCT-8/VCR cells, potentially leading to the suppression of MDR1 expression.	6-O-angeloylprenolin	15-35	ATP binding cassette subfamily B member 1	Homo sapiens	200-204
29928343-6	2018	Treatment with 6-O-angeloylplenolin inhibited the nuclear translocation of Y-box binding protein-1 in HCT-8/VCR cells treated with 6-O-angeloylplenolin, contributing to the negative regulation of MDR1.	6-O-angeloylprenolin	15-35	Y-box binding protein 1	Homo sapiens	75-98
29928343-6	2018	Treatment with 6-O-angeloylplenolin inhibited the nuclear translocation of Y-box binding protein-1 in HCT-8/VCR cells treated with 6-O-angeloylplenolin, contributing to the negative regulation of MDR1.	6-O-angeloylprenolin	15-35	ATP binding cassette subfamily B member 1	Homo sapiens	196-200
29928343-6	2018	Treatment with 6-O-angeloylplenolin inhibited the nuclear translocation of Y-box binding protein-1 in HCT-8/VCR cells treated with 6-O-angeloylplenolin, contributing to the negative regulation of MDR1.	6-O-angeloylprenolin	131-151	Y-box binding protein 1	Homo sapiens	75-98
29928343-6	2018	Treatment with 6-O-angeloylplenolin inhibited the nuclear translocation of Y-box binding protein-1 in HCT-8/VCR cells treated with 6-O-angeloylplenolin, contributing to the negative regulation of MDR1.	6-O-angeloylprenolin	131-151	ATP binding cassette subfamily B member 1	Homo sapiens	196-200
29928343-8	2018	In conclusion, 6-O-angeloylplenolin exhibited a MDR-reversing effect by downregulating MDR1 expression and could represent a novel adjuvant agent for chemotherapy.	6-O-angeloylprenolin	15-35	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
27835873-7	2017	Given that 6-OAP is a Skp1 inhibitor, our data suggest that this compound may target Skp1 and STAT3 to suppress Skp2, augmenting its anti-lung cancer activity.	6-O-angeloylprenolin	11-16	S-phase kinase associated protein 2	Homo sapiens	112-116
24137368-1	2013	6-O-angeloylplenolin (6-OAP) is a sesquiterpene lactone agent that has been previously demonstrated to inhibit the growth of multiple myeloma (MM) cells through mitotic arrest with accumulated cyclin B1.	6-O-angeloylprenolin	0-20	cyclin B1	Homo sapiens	193-202
24137368-1	2013	6-O-angeloylplenolin (6-OAP) is a sesquiterpene lactone agent that has been previously demonstrated to inhibit the growth of multiple myeloma (MM) cells through mitotic arrest with accumulated cyclin B1.	6-O-angeloylprenolin	22-27	cyclin B1	Homo sapiens	193-202
24137368-3	2013	Enhanced apoptosis was identified following a 48-h incubation with 6-OAP (0-10 muM) that induced a dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, anti-poly (ADP-ribose) polymerase (PARP).	6-O-angeloylprenolin	67-72	poly(ADP-ribose) polymerase 1	Homo sapiens	177-205
24137368-3	2013	Enhanced apoptosis was identified following a 48-h incubation with 6-OAP (0-10 muM) that induced a dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, anti-poly (ADP-ribose) polymerase (PARP).	6-O-angeloylprenolin	67-72	poly(ADP-ribose) polymerase 1	Homo sapiens	207-211
24137368-5	2013	The mechanism of 6-OAP cytotoxicity in all cell lines was associated with the induction of apoptosis with the presence of cleaved caspase-3 and PARP.	6-O-angeloylprenolin	17-22	poly(ADP-ribose) polymerase 1	Homo sapiens	144-148
31213669-5	2020	Pretreatment with 6-OAP (0.5-4 muM) dose-dependently attenuated LPS-induced NF-kappaB activation and oxidative stress, thus suppressed neuroinflammation in the cells.	6-O-angeloylprenolin	18-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-85
31213669-6	2020	In a mouse model of LPS-induced neuroinflammation, 6-OAP (5-20 mg kg-1 d-1, ip, for 7 days before LPS injection) dose-dependently inhibited the production of inflammatory cytokines, the activation of the NF-kappaB signaling pathway, and the expression of inflammatory enzymes in brain tissues.	6-O-angeloylprenolin	51-56	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	204-213
27835873-2	2017	Targeting of Skp1 by a small compound 6-O-angeloylplenolin (6-OAP) results in dissociation and degradation of Skp2 and mitotic arrest of lung cancer cells.	6-O-angeloylprenolin	38-58	S-phase kinase associated protein 1	Homo sapiens	13-17
27835873-2	2017	Targeting of Skp1 by a small compound 6-O-angeloylplenolin (6-OAP) results in dissociation and degradation of Skp2 and mitotic arrest of lung cancer cells.	6-O-angeloylprenolin	38-58	S-phase kinase associated protein 2	Homo sapiens	110-114
27835873-2	2017	Targeting of Skp1 by a small compound 6-O-angeloylplenolin (6-OAP) results in dissociation and degradation of Skp2 and mitotic arrest of lung cancer cells.	6-O-angeloylprenolin	60-65	S-phase kinase associated protein 1	Homo sapiens	13-17
27835873-2	2017	Targeting of Skp1 by a small compound 6-O-angeloylplenolin (6-OAP) results in dissociation and degradation of Skp2 and mitotic arrest of lung cancer cells.	6-O-angeloylprenolin	60-65	S-phase kinase associated protein 2	Homo sapiens	110-114
27835873-3	2017	Here, by using a proteome microarray containing 16,368 proteins and a biotinylated 6-OAP, we identified 99 proteins that could bind 6-OAP, with Skp1 and STAT3 sitting at the central position of the 6-OAP interactome.	6-O-angeloylprenolin	132-137	S-phase kinase associated protein 1	Homo sapiens	144-148
27835873-3	2017	Here, by using a proteome microarray containing 16,368 proteins and a biotinylated 6-OAP, we identified 99 proteins that could bind 6-OAP, with Skp1 and STAT3 sitting at the central position of the 6-OAP interactome.	6-O-angeloylprenolin	132-137	signal transducer and activator of transcription 3	Homo sapiens	153-158
27835873-3	2017	Here, by using a proteome microarray containing 16,368 proteins and a biotinylated 6-OAP, we identified 99 proteins that could bind 6-OAP, with Skp1 and STAT3 sitting at the central position of the 6-OAP interactome.	6-O-angeloylprenolin	132-137	S-phase kinase associated protein 1	Homo sapiens	144-148
27835873-3	2017	Here, by using a proteome microarray containing 16,368 proteins and a biotinylated 6-OAP, we identified 99 proteins that could bind 6-OAP, with Skp1 and STAT3 sitting at the central position of the 6-OAP interactome.	6-O-angeloylprenolin	132-137	signal transducer and activator of transcription 3	Homo sapiens	153-158
27835873-4	2017	6-OAP formed hydrogen bonds with Ser611/Ser613/Arg609 at the SH2 domain of STAT3 and inhibited the constitutive and interleukin-6-induced phosphorylated STAT3 (pSTAT3), leading to inhibitory effects on lung cancer cells and suppression of Skp2 transcription.	6-O-angeloylprenolin	0-5	signal transducer and activator of transcription 3	Homo sapiens	75-80
27835873-4	2017	6-OAP formed hydrogen bonds with Ser611/Ser613/Arg609 at the SH2 domain of STAT3 and inhibited the constitutive and interleukin-6-induced phosphorylated STAT3 (pSTAT3), leading to inhibitory effects on lung cancer cells and suppression of Skp2 transcription.	6-O-angeloylprenolin	0-5	interleukin 6	Homo sapiens	116-129
27835873-4	2017	6-OAP formed hydrogen bonds with Ser611/Ser613/Arg609 at the SH2 domain of STAT3 and inhibited the constitutive and interleukin-6-induced phosphorylated STAT3 (pSTAT3), leading to inhibitory effects on lung cancer cells and suppression of Skp2 transcription.	6-O-angeloylprenolin	0-5	signal transducer and activator of transcription 3	Homo sapiens	153-158
27835873-4	2017	6-OAP formed hydrogen bonds with Ser611/Ser613/Arg609 at the SH2 domain of STAT3 and inhibited the constitutive and interleukin-6-induced phosphorylated STAT3 (pSTAT3), leading to inhibitory effects on lung cancer cells and suppression of Skp2 transcription.	6-O-angeloylprenolin	0-5	S-phase kinase associated protein 2	Homo sapiens	239-243
27835873-6	2017	6-OAP inhibited tumor growth in SCID mice intravenously injected with lung cancer cells, and downregulated both STAT3 and Skp2 in tumor samples.	6-O-angeloylprenolin	0-5	signal transducer and activator of transcription 3	Mus musculus	112-117
27835873-6	2017	6-OAP inhibited tumor growth in SCID mice intravenously injected with lung cancer cells, and downregulated both STAT3 and Skp2 in tumor samples.	6-O-angeloylprenolin	0-5	S-phase kinase-associated protein 2	Mus musculus	122-126
27835873-7	2017	Given that 6-OAP is a Skp1 inhibitor, our data suggest that this compound may target Skp1 and STAT3 to suppress Skp2, augmenting its anti-lung cancer activity.	6-O-angeloylprenolin	11-16	S-phase kinase associated protein 1	Homo sapiens	22-26
27835873-7	2017	Given that 6-OAP is a Skp1 inhibitor, our data suggest that this compound may target Skp1 and STAT3 to suppress Skp2, augmenting its anti-lung cancer activity.	6-O-angeloylprenolin	11-16	S-phase kinase associated protein 1	Homo sapiens	85-89
27835873-7	2017	Given that 6-OAP is a Skp1 inhibitor, our data suggest that this compound may target Skp1 and STAT3 to suppress Skp2, augmenting its anti-lung cancer activity.	6-O-angeloylprenolin	11-16	signal transducer and activator of transcription 3	Homo sapiens	94-99
26474281-4	2015	By structure-based high-throughput virtual screening, we found some Skp1-targeting molecules including a natural compound 6-O-angeloylplenolin (6-OAP).	6-O-angeloylprenolin	122-142	S-phase kinase-associated protein 1	Mus musculus	68-72
26474281-4	2015	By structure-based high-throughput virtual screening, we found some Skp1-targeting molecules including a natural compound 6-O-angeloylplenolin (6-OAP).	6-O-angeloylprenolin	144-149	S-phase kinase-associated protein 1	Mus musculus	68-72
21755010-9	2011	6-OAP caused mitotic arrest, accompanied by activation of spindle assembly checkpoint and blockage of ubiquitiniation and subsequent proteasomal degradation of cyclin B1.	6-O-angeloylprenolin	0-5	cyclin B1	Homo sapiens	160-169
21755010-10	2011	Combined use of 6-OAP and bortezomib induced potentiated cytotoxicity with inactivation of ERK1/2 and activation of JNK1/2 and Casp-8/-3.	6-O-angeloylprenolin	16-21	mitogen-activated protein kinase 3	Homo sapiens	91-97
21755010-10	2011	Combined use of 6-OAP and bortezomib induced potentiated cytotoxicity with inactivation of ERK1/2 and activation of JNK1/2 and Casp-8/-3.	6-O-angeloylprenolin	16-21	mitogen-activated protein kinase 8	Homo sapiens	116-122
21755010-10	2011	Combined use of 6-OAP and bortezomib induced potentiated cytotoxicity with inactivation of ERK1/2 and activation of JNK1/2 and Casp-8/-3.	6-O-angeloylprenolin	16-21	caspase 8	Homo sapiens	127-133
21755010-11	2011	6-OAP overcame the protective effects of IL-6 and IGF-I on MM cells through inhibition of Jak2/Stat3 and Akt, respectively.	6-O-angeloylprenolin	0-5	interleukin 6	Homo sapiens	41-45
21755010-11	2011	6-OAP overcame the protective effects of IL-6 and IGF-I on MM cells through inhibition of Jak2/Stat3 and Akt, respectively.	6-O-angeloylprenolin	0-5	insulin like growth factor 1	Homo sapiens	50-55
21755010-11	2011	6-OAP overcame the protective effects of IL-6 and IGF-I on MM cells through inhibition of Jak2/Stat3 and Akt, respectively.	6-O-angeloylprenolin	0-5	Janus kinase 2	Homo sapiens	90-94
21755010-11	2011	6-OAP overcame the protective effects of IL-6 and IGF-I on MM cells through inhibition of Jak2/Stat3 and Akt, respectively.	6-O-angeloylprenolin	0-5	signal transducer and activator of transcription 3	Homo sapiens	95-100
21755010-11	2011	6-OAP overcame the protective effects of IL-6 and IGF-I on MM cells through inhibition of Jak2/Stat3 and Akt, respectively.	6-O-angeloylprenolin	0-5	AKT serine/threonine kinase 1	Homo sapiens	105-108
21755010-12	2011	6-OAP inhibited BMSCs-facilitated MM cell expansion and TNF-alpha-induced NF-kappaB signal.	6-O-angeloylprenolin	0-5	tumor necrosis factor	Homo sapiens	56-65